RHAPSODY - An Innovative Medicines Initiative Project for Precision Therapy and Prevention of Diabetes
RHAPSODY (“Risk Assessment and Progression of DIabetes”), a public-private consortium funded by the Innovative Medicines Initiative (IMI) and EFPIA Companies with contributions from academic institutions and SMEs, is a project focused on assessing the risk of progression of pre-diabetes to overt diabetes and of rapid deterioration of type 2 diabetes (T2D), a pandemic disease, which currently affects 285 million people worldwide.
RHAPSODY is a unique collaboration of leading public and private research groups, which will include over 100 researchers operating in 7 different scientific work packages. RHAPSODY is based on the availability of large population prospective cohorts, with unique collection of genetic, biochemical and clinical data. RHAPSODY will also beneficiate of extensive and unique resources developed in previous IMI projects. Combining new and existing data with the expertise of its partners, RHAPSODY will develop novel biomarkers to refine diagnosis leading to better patient stratification, promote prevention, and support innovative drug discovery for personalized management of diabetes.
Please read the official press release ( PDF) of the RHAPSODY launch.
SCIPROM has accompanied RHAPSODY since the project preparation phase. We now run the project office and support RHAPSODY through our expertise in management and communication.
For more information, please visit https://www.imi-rhapsody.eu